An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC - Scorecard - MDSpire
Advertisement
An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC
Clinical Scorecard: An Immune Niche Score Based on IHC Metrics Predicts Major Pathological Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer
At a Glance
Category
Detail
Condition
Resectable Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms
Integration of tertiary lymphoid structure (TLS) maturity, CD8–TLS proximity, CD8/FOXP3 balance, CD163/CD68 ratio, and PD-L1 tumor proportion score (TPS).
Target Population
Patients with resectable NSCLC undergoing neoadjuvant chemoimmunotherapy.
Care Setting
Oncology clinical practice.
Key Highlights
Remove the claim linking asthma history to higher pulmonary adverse-event rates.
Guideline-Based Recommendations
Diagnosis
Management
Consider neoadjuvant chemoimmunotherapy for resectable NSCLC patients.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The immune niche score should be presented without unsupported claims.
Clinical Best Practices
Incorporate immune niche score in clinical assessments of NSCLC.
